Basket Trials Hold Huge Promise. Get Important Insights to Help Ensure Success.
| This week's FierceBiotech is brought to you by Synteract.
Trouble viewing? Click here. |
| | Basket Trials Hold Huge Promise.
Get Important Insights to Help Ensure Success. | | | | | | In 2017, the FDA approved the first-ever cancer treatment for solid tumors having a common biomarker, regardless of where the cancer started. Today, basket trials hold huge promise to test therapies across multiple tumor types with a common biologic biomarker or mutation. However, basket trials also pose unique challenges and requirements. | | | | | | Download our guide to discover six key considerations that are critical to the success of oncology basket trials. | | | | | | Topics will include: | | | | |
| • | Assessing the complexities in basket trial study design | | | • | Understanding the challenges in identifying patients and sites for particular biomarkers | | | • | Ensuring the validity of results tested in the biomarker | | | • | Exploring alternative biopsy methods | | | • | Preparing to adapt and respond to shifts in outcomes | |
| | © 2019 Synteract. All rights reserved worldwide.
You are receiving this message due to the fact you previously provided your contact information to Synteract. Please refer to Synteract's privacy policy for additional information regarding Synteract's potential use of your information: https://www.synteract.com/Privacy |
|
| |
|
| Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
